ProShare Advisors
EIKN icon

ProShare Advisors’s Eikon Therapeutics EIKN Stock Holding History

ProShare Advisors’s Portfolio EIKN Stock Details EIKN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$127K Sell
15,757
-13,928
-47% -$140K ﹤0.01% 1655
2026
Q2 		$387K Buy
+29,685
New +$303K ﹤0.01% 1262

Other funds holding EIKN

Regents of the University of California
Regents of the University of California Oakland, California $6.64B AUM 23.46% 1-Year Est. Return
Y-Intercept (HK)
Y-Intercept (HK) Hong Kong $4.52B AUM 6.6% 1-Year Est. Return
Pavaki Capital Management
Pavaki Capital Management Pueblo, Colorado $294M AUM 34.46% 1-Year Est. Return
IFP Advisors
IFP Advisors Tampa, Florida $5.86B AUM 20.09% 1-Year Est. Return
Sterling Capital Management
Sterling Capital Management Charlotte, North Carolina $4.92B AUM 24.73% 1-Year Est. Return
State of Wyoming
State of Wyoming Cheyenne, Wyoming $1.29B AUM 32.25% 1-Year Est. Return
Farther Finance Advisors
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
Aspect Partners
Aspect Partners Fairfax, Virginia $264M AUM 15.76% 1-Year Est. Return
GAMMA Investing
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
Fortitude Family Office
Fortitude Family Office Scottsdale, Arizona $586M AUM 20.58% 1-Year Est. Return

ProShare Advisors's EIKN Position: Q3 2026 in Review

ProShare Advisors reduced its Eikon Therapeutics (EIKN) stake by 47% in Q3 2026, selling an estimated $140K and leaving 15,757 shares worth $127K. The position accounts for ﹤0.01% of the portfolio, ranked #1655.

ProShare Advisors first reported a position in EIKN in Q2 2026 and has held it in 2 quarters since. The position peaked at $387K in Q2 2026. 16 funds tracked by Wall St. Rank hold EIKN as of Q3 2026.

  • ProShare Advisors held 15,757 shares of Eikon Therapeutics worth $127K as of Q3 2026.
  • ProShare Advisors sold 13,928 Eikon Therapeutics shares in Q3 2026, an estimated $140K.
  • Eikon Therapeutics made up ﹤0.01% of ProShare Advisors's portfolio in Q3 2026, its #1655 holding.
  • ProShare Advisors first reported a position in Eikon Therapeutics in Q2 2026 and has held it in 2 quarters since.
  • ProShare Advisors's Eikon Therapeutics position peaked at $387K in Q2 2026.
  • 16 funds tracked by Wall St. Rank held Eikon Therapeutics as of Q3 2026.

Based on ProShare Advisors's 13F filing for Q3 2026, filed 29 Oct 2026.